Get the latest news on melanoma
11/6/2018
Rare Genetic Disorder Research Opens Door to Novel Melanoma Therapy
11/6/2018
CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
11/5/2018
Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma
11/3/2018
Melanoma: New guidelines for treatment from the AAD
11/2/2018
Specific CD8 T Cell States May Indicate Response to Melanoma Therapy
11/1/2018
Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)
10/22/2018
Follow-up study shows melanoma patients receiving adjuvant dabrafenib plus trametinib experience longer-term relapse-free survival benefit
08/31/2018
Combination Therapy May Offer Alternative Treatment Option for Advanced Melanoma
08/24/2018
Researchers discover epigenetic reason for drug resistance in a deadly melanoma
08/24/2018
Researchers find new therapy to prevent drug resistance for melanoma patients
08/22/2018
Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma
08/16/2018
Retinoic acid may improve immune response against melanoma
08/15/2018
Alton Memorial to host skin cancer screening Aug. 28
08/13/2018
PD-1 blockade provides ‘dramatic advance’ for the treatment of advanced melanoma
08/08/2018
Is Radioimmunotherapy a Path Forward for Melanoma?
07/27/2018
Keytruda is first I-O drug cleared for melanoma in China
07/26/2018
Cancer cells destroyed with two antipsychotic drugs
07/26/2018
CNDA approves KEYTRUDA for treatment of advanced melanoma
07/18/2018
Melanoma biomarkers predicting checkpoint blocker response
07/13/2018
Melanoma: Immunotherapy for brain metastases ‘doubles survival’
07/12/2018
Immunotherapy doubles survival rates for patients with melanoma brain metastases
07/11/2018
Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
07/11/2018
Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
05/19/2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
05/10/2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
05/01/2018
FDA Approves Adjuvant Combination Treatment For Resected Stage III Melanoma With BRAFV600 Mutations
04/14/2018
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
03/06/2018
Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
01/18/2018
Adjuvant Pembrolizumab Improves RFS in Melanoma
01/17/2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
12/20/2017
FDA Approves Adjuvant Opdivo for Melanoma Treatment
10/06/2017
Amgen’s Imlygic doubles response rate when added to checkpoint therapy
09/11/2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
07/24/2017
FDA Approves Ipilimumab for Pediatric Melanoma
07/07/2017
Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials
07/05/2017
Some Respond to Nivolumab After Melanoma Progression
06/29/2017
Study Raises Concern Over Accuracy of Melanoma Diagnoses
06/09/2017
Tanning Bed Use Declining Among U.S. Adults
06/09/2017